检索结果-南通市图书馆

Disproportional exaggerated aspartate transaminase is a useful prognostic parameter in late leptospirosis

World Journal of Gastroenterology 2005年第35期11卷 5553-5556页

作者： Ming-Ling Chang Chih-Wei Yang Jeng-Chang Chen Yu-Pin Ho Ming-Jeng Pan Cheng-Hui Lin Deng-Yn Lin Department of Hepatogastroenterology Chang Gung MemorialHospital 5 Fu-Shin Street Kweishan Taoyuan Taiwan China Department of Nephrology chang Gung MemorialHospital Taoyuan Taiwan China Department of Surgery Chang Gung MemorialHospital Taoyuan Taiwan China National Taiwan University Taipei Taiwan China Supported by the Chang Gung Medical Research Project fundNo. CMRPG 33014

AIM: To evaluate the hepatic dysfunction in leptospirosis is usually mild and resolved eventually. However,sequential follow-up of liver biochemical data remained lacking..METHODS: The biochemistry data and clinical symptoms of 11 sporadic patients were collected and analyzed, focusing on the impacts of leptospirosis upon liver biochemistry ***: The results disclosed that of the 11 cases, 5 or 45% died. The liver biochemistry data in the beginning of the disease course were only mildly ***, late exaggerated aspartate transaminase (AST)elevations were noted in three cases who finally died when compared with the typical course. Besides, significant higher AST/alanine transaminase (ALT) ratios (AARs) of the peak levels for transaminase were also noted in the cases who eventually succumbed. The mean±SD of AARs for the survival group and dead group were 5.65±2.27 (n = 5)and 1.86±0.64 (n = 6) respectively (P= 0.006). The ratios of the cases who finally died were all more than ***, the survival group's ratios were less than ***: Serial follow-up of transaminase might provide evidence to predict some rare evolutions in leptospirosis. If AST elevated progressively without a concomitant change of ALT, it might indicate an acute disease course with ensuing death. Additionally, AAR is another prognostic parameter for leptospirosis. Once the value was higher than 3.0, a grave prognosis is inevitable.

关键词： Leptospirosis Liver Aspartate transaminase alanine transaminase AST/ALT ratios

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

An Experimental Study on Drugs for Improving Blood Circulation and Removing Blood Stasis in Treating Mild Chronic Hepatic Damage

引用

Journal of Traditional Chinese Medicine 2001年第3期21卷 225-231页

作者：谢凤瑛李晓良孙克伟褚裕义曹晖谌宁生王伟华刘明德刘伟士毛德文毛树章 The First Affiliated Hospital of Hunan TCM College Changsha 410007

Large and small doses of drugs for improving blood circulation and removing blood stasis were used in model rats to treat mild chronic hepatic damage induced by carbon tetrachloride (CCl4). The results show that large dose of Dang Gui ([symbol: see text] Radix Angelicae Sinensis) and Dan Shen ([symbol: see text] Radix Salviae Miltiorrhizae) (drugs for regulating blood flow) and small dose of Yu Jin ([symbol: see text] Radix Curcumae) and Niu Xi ([symbol: see text] Radix Achyranthis Bidentatae) (drugs for activating blood flow) can significantly elevate the activity of SOD (P

关键词： alanine transaminase Animals Aspartate Aminotransferases Blood Circulation Blood Viscosity Carbon Tetrachloride Poisoning Chronic Disease Drugs, Chinese Herbal Hepatitis, Toxic Rats Rats, Wistar Superoxide Dismutase

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage

引用

World Journal of Gastroenterology 2004年第1期10卷 82-85页

作者： Johnny Sze The Institute of Molecular Biology The University of Hong KongHong KongChina

AIM:To evaluate the covalently closed circle DNA (cccDNA) level of hepatitis B virus (HBV) in patients' liver and sera. METHODS:HBV DNA was isolated from patients' liver biopsies and sera.A sensitive real-time PCR method,which is capable of differentiation of HBV viral genomic DNA and cccDNA,was used to quantify the total HBV *** total HBV viral DNA was quantitated by real-time PCR using a HBV diagnostic kit (PG Biotech,LTD,Shenzhen,China) described previously. RESULTS:For the first time,we measured the level of HBV DNA and cccDNA isolated from ten HBV patients' liver biopsies and *** the liver biopsies,cccDNA was detected from all the biopsy *** copy number of cccDNA ranged from from 0.03 to 173.1 per cell,the copy number of total HBV DNA ranged from 0.08 to 3 717 per *** ratio of total HBV DNA to cccDNA ranged from 1 to 3 *** the sera, cccDNA was only detected from six samples whereas HBV viral DNA was detected from all ten *** ratio of cccDNA to total HBV DNA ranged from 0 to 1.77%.To further investigate the reason why cccDNA could only be detected in some patients' sera,we performed longitudinal *** cccDNA was detected from the patients' sera with HBV reactivation but not from the patients' sera without HBV *** level of cccDNA in the sera was correlated with ALT and viral load in the HBV reactivation patients. CONCLUSION:HBV cccDNA is actively transcribed and replicated in some patients' hepatoo/tes,which is reflected by a high ratio of HBV total DNA vs *** of cccDNA in the liver biopsy will provide an end-point for the anti-HBV *** occurrence of cccDNA in the sera is an early signal of liver damage,which may be another important clinical parameter.

关键词： alanine transaminase Biopsy DNA, Circular DNA, Viral Hepatitis B virus Hepatitis B, Chronic Hepatocytes Humans Kinetics Liver Research Support, Non-U.S. Gov't Viral Load

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Interim results from ongoing PhaseⅢ placebo-controlled,randomized trial of hepcortespenlisimut-L for advanced hepatocellular carcinoma indication

引用

Hepatoma Research 2020年第1期6卷 11-18页

作者： Aldar S.Bourinbaiar Jigjidsuren Chinburen Purev Batchuluun Chogsom Munkhzaya DandiiOyungerel Dorjiin Dandii Galyna A.Kutsyna Hulan Tsogkhuu Marina G.Tarakanovskaya Alan A.Reid Vika Borisova Allen I.Bain Vichai Jirathitikal Immunitor Inc. VancouverBCV6K 2G8Canada National Cancer Center Ulaanbaatar 14000Mongolia National Center for Public Health Ulaanbaatar 13000Mongolia National Cancer Institute National Institutes of HealthBethesdaMD 20892USA Ekomed LLC Ulaanbaatar 13381Mongolia Immunitor China Ltd. ChaoyangBeijing 100027China

Aim:We aimed to further investigate the role of hepcortespenlisimut-L(Hepko-V5 or V5),a new oral immunotherapy developed by us,for hepatocellular carcinoma(HCC)***:The interim data from ongoing PhaseⅢplacebo-controlled,randomized trial were evaluated on the initial group of patients in advanced stage of HCC with emphasis on liver function and tumor marker alpha-fetoprotein ***,an in vitro study was undertaken to elucidate the mechanism of action of V5 by measuring with flow cytometry the expression of cytokines such as IL-2,INF-γ,and TNF-αand cell activation markers CD69 and Ki67 on CD4-and CD8-positive lymphocytes isolated from peripheral blood of healthy ***:As early as one month after treatment initiation,there was a clear improvement in alanine transaminase,aspartate transaminase,alkaline phosphatase,and bilirubin levels among HCC patients who received daily dose of V5,but not in the placebo ***,alpha-fetoprotein(AFP)levels among V5 recipients decreased,while in the ;placebo group they *** results are in line with in vitro observations indicating immune activation,as evidenced by many-fold enhancement of CD69,Ki67,and INF-γexpression and at the same time marked anti-inflammatory effect resulting in 10-fold decrease in TNF-αoutput and lack of influence on IL-2 ***:Hepcortespenlisimut-L,a tableted oral formulation derived from heat-inactivated pooled blood of patients with HCC and viral hepatitis shows beneficial clinical effect,as demonstrated by improvement in liver function and reduction of tumor marker AFP *** correlate with in vitro observations showing potent activation of the immune response and pronounced oral tolerance effect.

关键词： Hepatocellular carcinoma alpha-fetoprotein alanine transaminase aspartate transaminase IL-2 INF-γ TNF-α CD69 Ki67 CD4 CD8 T lymphocytes

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

HBV genotype characterization and distribution in patients with HBV-related liver diseases in Zhejiang Province, P. R. China: possible association of co-infection with disease prevalence and severity

引用

Hepatobiliary & Pancreatic Diseases International 2005年第4期4卷 535-543页

作者： Edward Zumbika Institute of Infectious Diseases the First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003People's Republic of China

BACKGROUND: There are 8 well-documented genotypes of hepatitis B virus (HBV) at this time point. Genotyping can be accomplished based on a partial sequence of hepatitis B virus (HBV) genome such as the pre-S or S gene. Several methods have been developed and used for HBV genotyping including direct sequencing, restriction fragment length polymorphism, line probe assay and enzyme-linked immunoassay. Recently, a novel, rapid and cost-effective genotyping method based on PCR amplification assay using type-specific primers that can identify all six major genotypes has been developed. This study was undertaken to characterise HBV genotypes and investigate the association between the prevalence of different genotypes and the severity of HBV-induced liver diseases. METHODS: Serum samples from carriers of HBV and patients with HBV-related liver diseases from Zhejiang Province were screened for viral serological markers using commercially available radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits. Serum HBV DNA load was determined by real-time detection PCR. A type-specific primer based the nested-PCR method was employed in the HBV genotyping. The genotype results obtained were confirmed by direct sequencing of nested PCR amplicons of the pre-S region. Ten samples of each genotype (B and C) were sequenced. RESULTS: The survey on a cohort of 125 HBV carriers in and around Hangzhou City, Zhejiang Province showed the existence of HBV genotypes A (0.8%), B (48%), C (40.8%), D (0.8%), mixed B and C (9.6%) and an absence of E and F genotypes. Distribution of HBV genotypes in patients with liver diseases revealed a statistically insignificant higher prevalence of genotype B in mild chronic hepatitis (CH). Among the three genotypes B, C and mixed B/C infections 11 (73.3%), 3 (20%) and 1 (6.7%), (P< 0.05), respectively in subjects with moderate CH, genotype B was significantly predominant. The infection patterns for genotypes B, C and B/C mixed in (i) liver c

关键词： hepatitis B virus chronic hepatitis B liver cirrhosis hepatocellular carcinoma hepatitis B e antigen hepatitis B virus DNA load viremia hepatitis B genotypes liver function tests alanine transaminase aspartate transaminase real-time detection PCR

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Monitoring the level of serum paraoxonase 1 activity in liver transplantation patients

引用

Hepatobiliary & Pancreatic Diseases International 2005年第2期4卷 178-181页

作者： Gen-Yun Xu, Guo-Cai Lv, Yu Chen, Yong-Chuan Hua, Shen-Mei Zhu and Yi-Da Yang Hangzhou, China Clinical Laboratory, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China Clinical Laboratory First Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310003 China. genyunxu@***

BACKGROUND: Paraoxonase 1(PON1) is an ester hydro- lase in serum and in the liver. Studies have suggested that PON1 measurement to the current battery of tests may im- prove the evaluation of chronic liver diseases. The aim of this study was to investigate the clinical significance of mo- nitoring the level of serum PON1 activity in liver transplan- tation patients. METHODS: A series of biochemical indexes were moni- tored in preoperative, operative and postoperative serum samples of 17 liver-transplanted patients. The change of se- rum PON1 level and its relations with other biochemical in- dexes were analyzed. RESULTS: PON1 was distributed normally in the healthy population and its reference value ranged from 45.5 to 265.8 U/mL. The PON1 level of all patients was lower than that of control group significantly (P<0.001); the level be- gan to elevate continuously 5 minutes after opening of the portal vein and was higher than that 90 minutes after open- ing of the portal vein ( P <0.05). Two days after operation it was still higher than the normal. The levels of serum ALT and AST elevated more significantly after opening of the portal vein than before operation and they were higher than the normal values till 2 days after the operation. CONCLUSIONS: The level of PON1 in serum may be taken as one of the effective indexes to assess whether the implant is alive and to monitor liver function of the patient together with other tests.

关键词： paraoxonase 1 liver transplantation alanine transaminase aspartate transaminase γ-glutamyltransferase cholinesterase

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B

引用

Chinese Medical Journal 2002年第12期115卷 1814-1818,148-149页

作者：姚光弼崔振宇王宝恩姚集鲁曾民德上海静安区中心医院临床免疫中心上海200040 北京地坛医院门诊部北京100011 北京友谊医院肝病研究中心北京100050 中山大学第三医院传染病科广州510130 上海仁济医院消化病研究室上海200002

OBJECTIVE: To evaluate the long-term efficacy and safety of lamivudine therapy for the treatment of chronic hepatitis B and the clinical influence of emergence of tyrosine methionine aspartic acid (YMDD) motif mutation of hepatitis B virus (HBV). METHODS: This multicenter, double-blind, randomized, placebo controlled trial began in 1996. A total of 429 patients with HBsAg, HBeAg and HBV CNA positives were enrolled. They were randomized to receive either lamivudine 100 mg daily (n = 322) or placebo (n = 107) on 3 : 1 ratio for the first 12 weeks. Thereafter all patients were offered open label lamivudine treatment and assessed every 4 weeks for a total of 104 weeks. RESULTS: After 1 year treatment 72.7% patients (285/392) had a sustained serum HBV DNA response. HBV DNA continued to be substantially suppressed at the second year, except in patients with the emergence of YMDD mutation whose mean HBV DNA levels increased to 86 Meq/ml (bDNA assay) but were much more lower than that of pre-treatment baseline level. lamivudine therapy resulted in increased HBeAg loss and HBeAg/anti-HBe seroconversion, which were correlated with both baseline alanine transaminase (ALT) levels and also with duration of lamivudine treatment. HBeAg loss was achieved in 26.8% of patients with ALT > 1-fold upper limit of normal at 2 yeas and in 35.6% and 55.6% of patients with ALT > 2-fold upper limit of normal and ALT > 5-fold upper limit of normal, respectively. For HBeAg seroconversion, these figures were 17.4%, 22.2%, and 33.3% respectively. By the end of 2 years, ALT levels were remained in normal ranges in 50.3% whose ALT were abnormal before treatment, and in 83% whose ALT were mormal before treatment. YMDD mutation were developed in 49.7% of the patients. Their serum HBV DNA levels were slightly increased to bDNA median level 86 Meq/ml and 15% of the patients they were ALT exceeded baseline levels. Four patients clinically flared-up and recovered after stop treatment. The adverse drug re

关键词： Adolescent Adult Aged alanine transaminase Antiviral Agents DNA, Viral DNA-Directed DNA Polymerase Double-Blind Method Hepatitis B e Antigens Hepatitis B virus Hepatitis B, Chronic Humans Lamivudine Middle Aged Research Support, Non-U.S. Gov't

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：